Key result
Sirtuin1 overexpression ameliorated PKC-ζ-induced cardiac hypertrophy by suppressing PKC-ζ acetylation and phosphorylation.
Why the study?
Does sirtuin1 activation reduce cardiac hypertrophy in rat models?
Does sirtuin1 activation reduce cardiac hypertrophy in rat models?
Sirtuin1 acts as an endogenous negative regulator of PKC-ζ, and its activation ameliorates cardiac hypertrophy in preclinical models.
Answers are grounded in this paper and cite their sources.
May reduce hypertrophy in rat models; leaves open clinical translation.
BACKGROUND AND PURPOSE: Activation of PKC-ζ is closely linked to the pathogenesis of cardiac hypertrophy. PKC-ζ can be activated by certain lipid metabolites such as phosphatidylinositol (3,4,5)-trisphosphate and ceramide. However, its endogenous negative regulators are not well defined. Here, the role of the sirtuin1-PKC-ζ signalling axis and the underlying molecular mechanisms were investigated in cardiac hypertrophy. EXPERIMENTAL APPROACH: Cellular hypertrophy in cultures of cardiac myocytes, from neonatal Sprague-Dawley rats, was monitored by measuring cell surface area and the mRNA levels of hypertrophic biomarkers. Interaction between sirtuin1 and PKC-ζ was investigated by co-immunoprecipitation and confocal immunofluorescence microscopy. Sirtuin1 activation was enhanced by resveratrol treatment or Ad-sirtuin1 transfection. A model of cardiac hypertrophy in Sprague-Dawley rats was established by abdominal aortic constriction surgery or induced by isoprenaline in vivo. KEY RESULTS: Overexpression of PKC-ζ led to cardiac hypertrophy and increased activity of NF-κB, ERK1/2 and ERK5, which was ameliorated by sirtuin1 overexpression. Enhancement of sirtuin1 activity suppressed acetylation of PKC-ζ, hindered its binding to phosphoinositide-dependent kinase 1 and inhibited PKC-ζ phosphorylation in cardiac hypertrophy. Consequently, the downstream pathways of PKC-ζ' were suppressed in cardiac hypertrophy. This regulation loop suggests a new role for sirtuin1 in mediation of cardiac hypertrophy. CONCLUSIONS AND IMPLICATIONS: Sirtuin1 is an endogenous negative regulator for PKC-ζ and mediates its activity via regulating the acetylation and phosphorylation in the pathogenesis of cardiac hypertrophy. Targeting the sirtuin1-PKC-ζ signalling axis may suggest a novel therapeutic approach against cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied Cardiac hypertrophy. Sirtuin1 activation (resveratrol or Ad-sirtuin1 transfection) was evaluated on Cardiac hypertrophy and PKC-ζ activity. Sirtuin1 overexpression ameliorated PKC-ζ-induced cardiac hypertrophy by suppressing PKC-ζ acetylation and phosphorylation.
Synapse has enriched 10 related papers. Consider them for comparative context: